aTyr Pharma Inc (NASDAQ:LIFE) has earned an average rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $1.01.
A number of equities research analysts have commented on LIFE shares. ValuEngine raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research downgraded shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. Finally, William Blair reissued a “market perform” rating on shares of aTyr Pharma in a research report on Tuesday, March 26th.
An institutional investor recently raised its position in aTyr Pharma stock. Renaissance Technologies LLC grew its stake in aTyr Pharma Inc (NASDAQ:LIFE) by 107.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,107,025 shares of the biotechnology company’s stock after buying an additional 573,164 shares during the period. Renaissance Technologies LLC owned 3.71% of aTyr Pharma worth $899,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 30.47% of the company’s stock.
aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings data on Monday, March 25th. The biotechnology company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. On average, research analysts forecast that aTyr Pharma will post -0.8 earnings per share for the current year.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
Further Reading: Do Tariffs Work?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.